From: CBER Exec. Sec. <cber_execsec@fda.hhs.gov>
Sent: Monday, June 29, 2026 4:03 PM
To: Aaron Siri [redacted]>; Elizabeth Brehm [redacted]>
Subject: FDA CBER response to your letter on behalf of the Informed Consent Action Network (ICAN)

Dear Mr. Siri:

Thank you for your letters dated February 7, 2022, and May 23, 2022, on behalf of the Informed Consent Action Network (ICAN) regarding individuals who received a first dose of COVID-19 mRNA vaccine but did not receive a second dose according to the recommended schedule. Your inquiry was routed to the Center for Biologics Evaluation and Research (CBER) at FDA for response.

The Food and Drug Administration takes vaccine safety monitoring seriously and works to continuously evaluate the safety profile of all authorized and approved vaccines, including COVID-19 vaccines.

For information regarding vaccination patterns and the data referenced in your inquiry, we recommend directing your questions to the Centers for Disease Control and Prevention (CDC). Data has been published in the CDC's Morbidity and Mortality Weekly Report (MMWR), which may address the specific information you are seeking.
We appreciate your organization's interest in vaccine safety. The FDA remains committed to transparency and will continue to make safety data and analyses available to the public through our website and scientific publications.

Sincerely,

CBER Executive Operations
Center for Biologics Evaluation and Research
U.S. Food and Drug Administration
Email: cber_execsec@fda.hh.gov